Interleukin-18 and coronary artery lesions in patients with Kawasaki disease

J Chin Med Assoc. 2013 Aug;76(8):438-45. doi: 10.1016/j.jcma.2013.04.005. Epub 2013 Jun 13.

Abstract

Background: Interleukin-18 (IL-18) plays an important role in mediating cytokine cascade leading to coronary artery lesions (CALs) in Kawasaki disease (KD). However, our research suggested that the literature regarding IL-18 and KD is limited. Consequently, this study aimed to evaluate the correlation between IL-18 and CALs in patients with KD.

Methods: In this prospective study of 14 children with KD (seven without and seven with CALs in the acute phase), we obtained patient measurements of a series of serum IL-18 levels in the acute, subacute, and convalescent phases. Serum IL-18 levels were measured with a Bio-Plex cytokine assay. Control samples were obtained from 18 febrile children with viral infection.

Results: Compared with febrile controls, patients with acute-stage CALs [postintravenous immunoglobulin (post-IVIG) period] had a significantly higher IL-18 level (88.4 ± 20.7 vs 56.0 ± 35.0 pg/mL, p = 0.006). However, those without acute-stage CALs (post-IVIG period) lacked similarly elevated IL-18 level readings (62.0 ± 40.6 vs 56.0 ± 35.0 pg/mL, p = 0.762). The IL-18 level of patients with acute-stage CALs did not decrease significantly until the convalescent phase (97.4 ± 55.8 vs 38.7 ± 22.6 pg/mL, p = 0.018), but for those without CALs, it decreased significantly in the subacute phase (60.2 ± 37.4 vs 23.6 ± 13.8 pg/mL, p = 0.018). In the subacute stage, there was a significant difference of IL-18 level between patients with and without acute-stage CALs (p = 0.048).

Conclusion: Our data show that IL-18 levels were elevated in the acute phase of KD and might be related to the formation of CALs.

Keywords: Kawasaki disease; coronary artery lesions; interleukin-18.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • C-Reactive Protein / analysis
  • Child
  • Child, Preschool
  • Coronary Artery Disease / etiology*
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Infant
  • Infant, Newborn
  • Interferon-gamma / biosynthesis
  • Interleukin-18 / blood
  • Interleukin-18 / physiology*
  • Male
  • Mucocutaneous Lymph Node Syndrome / complications
  • Mucocutaneous Lymph Node Syndrome / immunology*
  • Prospective Studies

Substances

  • Immunoglobulins, Intravenous
  • Interleukin-18
  • Interferon-gamma
  • C-Reactive Protein